Gland Pharma, a company in the Pharmaceuticals industry, reported revenue of ₹1,834 crore and net profit of ₹291 crore for the September 2026 quarter.
Gland Pharma (NSE: GLAND) closed at ₹3,331.90 on 20 Nov 2026, up 83.3% over the past year. Its market capitalisation is ₹54,980 crore and it trades at 43.9 times earnings.
Established in Hyderabad, India in 1978, Gland Pharma has grown over the years from a contract manufacturer of small volume liquid parenteral products, to become one of the largest and fastest growing injectable-focused companies, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India and other markets. We operate primarily under a business to business (B2B) model and have an excellent track record in the development, manufacturing and marketing of complex injectables. This presence across the value chain has helped us witness exponential growth. We are promoted by Shanghai Fosun Pharma, a global pharmaceutical major.
Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.